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Abstract
Introduction Musculoskeletal (MSK) injuries are a
frequent cause for emergency department (ED) visits in
children. MSK injuries are associated with moderate-to-
severe pain in most children, yet recent research confirms
that the management of children’s pain in the ED remains
inadequate. Clinicians are seeking better oral analgesic
options for MSK injury pain with demonstrated efficacy and
an excellent safety profile. This study aims to determine
the efficacy and safety of adding oral acetaminophen
or oral hydromorphone to oral ibuprofen and interpret
this information within the context of parent/caregiver
preference.
Methods and analysis Using a novel preference-
informed complementary trial design, two simultaneous
trials are being conducted. Parents/caregivers of children
presenting to the ED with acute limb injury will be
approached and they will decide which trial they wish
to participate in: an opioid-inclusive trial or a non-opioid
trial. Both trials will follow randomised, double-blind,
placebo-controlled, superiority-trial methodology and will
enrol a minimum of 536 children across six Canadian
paediatric EDs. Children will be eligible if they are 6 to 17
years of age and if they present to the ED with an acute
limb injury and a self-reported verbal Numerical Rating
Scale pain score ≥5. The primary objective is to determine
the effectiveness of oral ibuprofen+oral hydromorphone
versus oral ibuprofen+oral acetaminophen versus oral
ibuprofen alone. Recruitment was launched in April 2019.
Ethics and dissemination This study has been approved
by the Health Research Ethics Board (University of Alberta),
and by appropriate ethics boards at all recruiting centres.
Informed consent will be obtained from parents/guardians
of all participants, in conjunction with assent from the
participants themselves. Study data will be submitted
for publication regardless of results. This study is funded
through a Canadian Institutes of Health Research grant.
Trial registration number NCT03767933, first registered
on 07 December 2018.

Strengths and limitations of this study
►► This study employs a novel design involving two

simultaneously run, complementary, randomised
controlled trials.
►► Participating families will choose in which trial they
wish to participate, thus engaging and empowering
them as a key participant in healthcare research
decision-making.
►► This study will collect preference and opinion data
from families, in order to better understand their analgesic decision-making for their children.
►► We expect that some parents/caregivers will be hesitant to accept opioids thus leading to an imbalance
in the pace of recruitment between the two trials.
►► Given the sample size, this study will not be able to
provide definitive evidence regarding rare but serious adverse events.

Introduction
Musculoskeletal (MSK) injuries are very
common and are associated with moderate-
to-severe pain for most children.1 2 Despite
three decades of research in this area, recent
evidence confirms that paediatric pain
management in the emergency department
(ED) is still suboptimal.3–5 Previous studies
have demonstrated that only 35% of children
presenting to a paediatric ED with fractures
or severe sprains received any analgesic.6 7
The American Academy of Pediatrics
recommends acetaminophen, ibuprofen and
opioids as the top three medication choices
for the treatment of acute pain in children.8
These are also the top three most commonly
used analgesics for children with MSK
injury.3 4 6 9 10 However, there has recently been
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Methods and analysis
This study will be conducted with a novel preference-
informed complementary trial design and is comprised
of two simultaneous ‘parallel’ trials. Eligible parent/
caregiver-child pairs will decide which trial they wish to
participate in: a three-armed opioid-inclusive trial (the
2

Opioid trial) or a two-armed non-opioid trial (the Non-
Opioid trial). Once the parent/caregiver and child have
chosen their preferred trial, conduct within each trial
will follow traditional randomised, double-blind, parallel
assignment, placebo-
controlled superiority trial methodology. Study endpoints will be identical for both trials
within this study. The study protocol is reported using the
Standard Protocol Items: Recommendations for InterPatient-
Reported Outcomes reporting
ventional Trials-
guidelines.29 (see table 1)
Study setting
This study will be conducted in six paediatric EDs across
Canada: (1) Stollery Children’s Hospital (Edmonton,
Alberta) (coordinating site), (2) Alberta Children’s
Hospital (Calgary, Alberta), (3) Winnipeg Children’s
Hospital (Winnipeg, Manitoba), (4) Children’s Hospital
at London Health Sciences Centre (London, Ontario),
(5) CHEO (Ottawa, Ontario), and (6) Centre Hospitalier
Universitaire Ste-Justine (Montreal, Quebec). The annual
ED census for recruiting centres ranges from 30 000 to 80
000 patient visits. Study recruitment began on 20 April
2019 and is expected to be completed within 18 months.
Eligibility and exclusion criteria
Children will be eligible if they are 6 to 17 years, presenting
to the ED with an acute limb injury (<24 hours old) that
is neither obviously deformed nor having neurovascular
compromise, and have a self-reported verbal Numerical
Rating Scale pain score ≥5 at triage. This age group was
chosen as fractures rarely occur under this age, and a
consistent and validated pain measurement tool can be
employed across this age range.
Children will be excluded if they meet any of the
following criteria: (a) require immediate intravenous or
intranasal pain medications, (b) have known hypersensitivity to study medications, (c) receive acetaminophen or
non-steroidalanti-inflammatory drug within 3 hours prior
to recruitment, (d) receive opioids within 1 hour prior
to recruitment, (e) parent/caregiver or child cognitive
impairment precluding the ability to self-report pain or
respond to study questions, (f) injury suspected to be due
to non-accidental trauma or child abuse, (g) suspected
multi-limb fracture, (h) chronic pain that necessitates
daily analgesic use, (i) known hepatic or renal disease/
dysfunction, (j) known bleeding disorder, (k) known
pregnancy, (l) vomiting that precludes the ability to take
oral medications, (m) parent/caregiver and/or child’s
inability to communicate fluently in English or French in
the absence of a native language interpreter, (n) parent/
caregiver unavailable for follow-up or (o) previous enrolment in this study.
Study Interventions and rescue medications
If a family chooses the Opioid trial, their child will
be randomised to one of the three treatment arms:
(a) oral ibuprofen+acetaminophen placebo+hydromorphone placebo, OR (b) oral ibuprofen+oral
Ali S, et al. BMJ Open 2020;10:e035177. doi:10.1136/bmjopen-2019-035177
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a concerted movement to limit opioid use in children,
due, in large part, to the current Opioid Crisis.11 12 Clinicians are increasingly less likely to prescribe oral opioids
to young children, and caregivers are increasingly less
willing to administer them.5 The fear of adverse events,
particularly respiratory depression and deep sedation,
are other important reasons to explain the reluctance to
prescribe an opioid to children with moderate-to-severe
pain.13
Clinicians are currently seeking optimal (and for many,
non-opioid) oral analgesic options with the best efficacy
and safety profile. It is known that the under-treatment
of children’s pain is partly due to a lack of evidence to
support clinician decision-making in choosing the most
effective medication.4 14 A recently published systematic
review of MSK injury pain management concluded that
an optimal analgesic approach could not be identified at
this time.15 Very few paediatric studies of analgesic combination therapy for MSK injury exist, and extrapolation
from adult data can be misleading, both in establishing
the correct dose and in assessing effect.15–18 Research
has demonstrated that a combination of oral morphine
with ibuprofen was no more effective and was less safe
than oral ibuprofen alone for children’s MSK pain.16 Two
clinical trials of oral morphine versus ibuprofen have
shown that oral morphine was not superior to ibuprofen
alone.19 20 Similarly, oxycodone was no more effective and
was less safe than ibuprofen for post-discharge fracture
pain.21 Further, tramadol, hydrocodone and codeine are
not recommended for widespread use in children due to
safety concerns.22–25 There is some emerging work from
non-ED settings to suggest that oral hydromorphone may
be an effective alternative to oral morphine and oxycodone.26 27 Oral hydromorphone is a long-acting opioid
analgesic with a duration of action up to 4 hours and is
more potent than oral morphine, but with fewer side
effects.28 Both oral hydromorphone and ibuprofen’s peak
analgesic action occurs at 60 min post administration.
The proposed study aims to determine if acetaminophen or hydromorphone, when added to ibuprofen,
offers more clinical pain relief than ibuprofen alone,
for children with an acute MSK injury. Further, it will
determine if the combination of hydromorphone and
ibuprofen is more clinically effective than the combination of acetaminophen with ibuprofen. This study, which
will consist of two clinical trials, will inform healthcare
decisions by providing evidence for the effectiveness
and safety of commonly prescribed analgesic agents, and
compare them to the most commonly used monotherapy,
ibuprofen.3 6
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Data category

Information

Primary registry and trial identifying
number

ClinicalTrials.gov, NCT03767933.

Date of registration in primary registry

07 December 2018.

Secondary identifying numbers

University of Alberta Research Ethics Board # Pro00073476.

Source(s) of monetary or material support Canadian Institutes of Health Research SPOR Innovative Clinical Trials Grant (MYG151207).
Primary sponsor

University of Alberta.

Secondary sponsor(s)

–

Contact for public queries

Dr Samina Ali 780.248.5575 sali@ualberta.ca

Contact for scientific queries

Dr Samina Ali 780.248.5575 sali@ualberta.ca

Public Title

The No OUCH Study

Scientific Title

A Study of Non-Steroidal or Opioid Analgesia Use for Children with Musculoskeletal
Injuries: The No OUCH Study

Countries of recruitment

Canada.

Health condition(s) or problem(s) studied

Acute musculoskeletal injury.

Intervention(s)

Opioid trial: (A) Oral hydromorphone (0.05 mg/kg, max 5 mg)+oral ibuprofen (10 mg/kg,
max 600 mg).
(B) Oral acetaminophen (15 mg/kg, max 1000 mg)+oral ibuprofen (10 mg/kg, max 600 mg).
Non-Opioid trial: Oral acetaminophen (15 mg/kg, max 1000 mg)+oral ibuprofen (10 mg/kg,
max 600 mg).
(Comparator for both trials: Oral ibuprofen 10 mg/kg, max 600 mg)

Key inclusion and exclusion criteria

To be eligible to participate in this study, an individual must meet all of the following
criteria: (1) Child aged 6 to 17 years, (2) Presenting to the emergency department with
an acute limb injury (<24 hours old) that is neither obviously deformed nor having
neurovascular compromise (as assessed by the triage nurse), (3) Self-reported pain score
>5 on the 0 to 10 verbal Numerical Rating Scale at triage.
 Exclusion criteria include: (1) Deemed to require immediate intravenous or intranasal
pain medications by the clinical team, (2) Previously known hypersensitivity to study
medications, (3) Acetaminophen or NSAID use within 3 hours prior to recruitment,
(4) Opioid use within 1 hour prior to recruitment, (5) Caregiver and/or child cognitive
impairment precluding the ability to self-report pain or respond to study questions, (6)
Injury suspected to be due to non-accidental trauma/child abuse (as assessed by the
triage nurse or reported by the family), (7) Suspected multi-limb fracture, (8) Chronic
pain that necessitates daily analgesic use, (9) Hepatic or renal disease/dysfunction, (10)
Bleeding disorder, (11) Known pregnancy, (12) Vomiting that precludes the ability to take
oral medications (as determined by the family), (13) Caregiver and/or child’s inability
to communicate fluently in English or French in the absence of a native language
interpreter, (14) Caregiver unavailable for follow-up or (15) Previous enrolment in the No
OUCH study.

Study type

Randomised, double-blind, placebo-controlled superiority trials.

Date of first enrolment

20 April 2019

Sample size

536

Recruitment status

Actively recruiting.

Primary outcome(s)

The primary efficacy outcome will be the self-reported pain score at 60 min, using an
11-point, 0 to 10, verbal Numerical Rating Scale.

Key secondary outcomes

The principal safety endpoint will be the proportion of children with adverse events related
to study drug administration.

Ethics review

University of Alberta Research Ethics Board # Pro00073476.

Completion date

–

Summary results

–

IPD sharing statement

De-identified data can be shared, on a case-by-case basis, on discussion with the
principal investigator.

IPD, Individual Participant Data; NSAID, non-steroidal anti-inflammatory drug.
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Table 1 WHO trial registration data set
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Randomisation, allocation concealment and blinding
Randomisation will be determined using a secure online
centralised randomisation tool hosted by the Women and
Children’s Health Research Institute (WCHRI, University of Alberta).34 Participants will be allocated via a kit
number. A statistician will oversee the generation of a
randomised listing of the treatment by kit number using
a 1:1:1 allocation scheme for the Opioid trial, and a 1:1
allocation scheme for the Non-Opioid trial. This will be
further stratified by centre using block-randomisation with
variable block sizes. These randomisation lists, which will
be sent directly by the statistician to the participating site’s
research pharmacy team, will be used by each participating
site’s research pharmacy to create pre-packaged, sequential
study kits for each trial. Research nurses will then allocate
the kits to enrolled participants in a sequential fashion.
Study participants, research nurses (the outcome assessors), ED staff and data analysts will all be blinded with
respect to the intervention. In the rare occurrence where
a treating physician feels that knowing what the child has
received will impact further clinical care, the study blind
can be broken by the clinical team for patient safety. The
protocol for unblinding will involve the research nurse
logging in to a secure web-based unblinding system with
REDCap. However, only the treating physician will ‘click’
on the button to reveal the study medications administered. Thus, parents/caregivers, children and research
staff will remain blinded.
Recruitment and data collection
The patient’s initial assessment on arrival to the ED will
be performed by a triage nurse. Triage nurses, research
4

nurses or their designate will identify potentially eligible
participants. Research nurses will be present in enrolling
EDs up to 16 hours a day to screen children and assess
eligibility based on the inclusion and exclusion criteria
outlined above. Research nurses will follow site-specific
Research Ethics Board (REB) guidelines regarding
approaching families for research studies. Verbal consent
for screening will be obtained from families and documented. For eligible parent/caregiver-
child pairs who
express interest in study participation, an ED physician
will confirm eligibility, and the research nurse or designate will complete consent and assent, as appropriate
(online supplementary appendix 1).
After obtaining written informed consent from the
parent/caregiver, and assent from the child where appropriate, the research nurse will determine preference for
study trial (ie, Opioid or Non-Opioid). In keeping with
the ethical requirements of the involved Canadian institutions, we will have consent forms for parent/caregivers,
assent forms for children and mature minor consent
forms for both accompanied and unaccompanied youth
who are deemed to be mature minors. All of these forms
are written in a manner to reflect the reading and comprehension capacity of the target groups. If the parent/caregiver and child pair do not voice a trial preference, they
will be enrolled in the Opioid trial as it contains all three
possible medication combinations offered in the study,
as outlined in the consent form. The research nurse
will administer the study medications according to the
randomisation scheme for that chosen trial (figure 1). If
a participant vomits within 30 min of drug administration,
it will be repeated once in accordance with current clinical and research practice.35 The parent/caregiver will
be asked to complete a brief survey in the ED to explore
their reasons for choosing their study trial (see online
supplementary appendix 2).
Following study drug administration, the research nurse
will monitor the participant for up to 120 min, with safety
and efficacy measures recorded at the time of recruitment (T-R), time of study drug administration (T-0), at 30
min, 60 min, 90 min and 120 min post-study drug administration (T-30, T-60, T-90, T-120 respectively), at the time
of medical examination (T-ME) and as soon as possible
following X-ray (T-XR). All study measures at T-30, T-60,
T-90 and T-120 will be collected within 15 min of the
designated time point (ie, ±15 min). All study measures
for T-ME and T-XR will be collected within 30 min of the
designated time point. If a patient is discharged prior to
T-120, the study measures will be recorded one last time
at the time of discharge.
Pain scores will be measured on the verbal Numerical Rating Scale (vNRS), Visual Analogue Scale (VAS)
and Faces Pain Scale-Revised (FPS-R) at each study time
point.36 37 In addition, the research nurse will also evaluate
the presence of adverse events (eg, nausea, vomiting),
record vital signs (pulse, blood pressure, respiratory rate,
oxygen saturation) and evaluate sedation level using the
Ramsay Sedation Scale.38 Reporting of adverse events will
Ali S, et al. BMJ Open 2020;10:e035177. doi:10.1136/bmjopen-2019-035177
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acetaminophen+hydromorphone
placebo,
OR
(c) oral ibuprofen+acetaminophen placebo+oral
hydromorphone.
If a family chooses the Non-Opioid trial, their child will
be randomised to one of the two treatment arms: (a) oral
ibuprofen+acetaminophen placebo, OR (b) oral ibuprofen+oral acetaminophen.
Ibuprofen will be dosed as 10 mg/kg (maximum
600 mg), acetaminophen as 15 mg/kg (maximum
1000 mg) and oral hydromorphone as 0.05 mg/kg
(maximum 5 mg).
Given the consistent recommendations that ibuprofen
will be the first-
line therapy for acute MSK injury
pain,15 30–32 and the fact that it is the medication of choice
for triage-
initiated pain protocols at most Canadian
paediatric EDs,33 ibuprofen will serve as the comparator
(standard of care) for both trials.
All study medications and placebos will be administered as a single oral dose in liquid form. No other medications will be administered as part of the study. However,
enrolled patients will be eligible to receive additional
analgesia at any time if requested and/or deemed necessary by the clinical team. The treating physician will order
rescue analgesia at their discretion. Any such co-interventions, including non-
pharmacologic interventions (eg,
ice, splinting) will be documented.

Open access

Study interventions.

be in keeping with Health Canada regulations and REB
guidelines. Prior to their discharge from the ED, both the
child and parent/caregiver will be asked to rate acceptability of the study medication received during the trial
using a Likert scale. (figure 2)
Two brief 10-min follow-up surveys will be completed
with the parent/caregiver following their child’s
discharge from the ED. Parents/caregivers will have the
option of completing these over the phone or online via
a secure email link. Non-responders to email contact and
those who prefer phone follow-up will be called three to
five times depending on local REB requirements. The
first follow-up survey, conducted at 1 to 3 days post ED
discharge, will determine the occurrence of any adverse
events since discharge. The second follow-up survey will
be completed at 1 to 2 weeks post ED discharge, to determine parent/caregiver comfort and satisfaction with
at-home pain management and the extent of functional
limitations for their child.

To achieve adequate participant enrolment to reach
target sample size, we will monitor the monthly recruitment targets and have regular (every 4 to 8 week) team
meetings to allow for timely implementation of procedural changes. There are no plans for patient follow-up
beyond the 2-week study period, given that only one dose
of study medications will be administered. All study scripts
and data collection tools will be available in English and
French.
Outcome measures
The Primary Efficacy Outcome will be the self-reported
vNRS pain score at 60 min post study drug administration. The vNRS, ranging from 0 (no pain) to 10 (worst
pain imaginable), is the most commonly used, responsive pain measurement tool for this study age group.39 It
has been successfully employed in several children’s pain
studies,40 41 and is validated for the age range of children
included in this study.42 The 60 min primary outcome time

Figure 2 Schedule of study measures. BP,blood pressure; ED, emergency department; FPS-R,Faces Pain Scale-Revised; HR,
heart rate; O2 sat, oxygensaturation; RR, respiratory rate; RSS, RamsaySedation Scale; T-ME, time of medical examination; T-
R, time ofrecruitment; T-XR, time following X-ray; T-0, timeof study drug administration; T-30, T-60, T-90, T-120, 30 min,60 min,
90 minand 120 min, respectively; vNRS, verbal Numerical Rating Scale; VAS, VisualAnalogue Scale.
Ali S, et al. BMJ Open 2020;10:e035177. doi:10.1136/bmjopen-2019-035177
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Figure 1
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Secondary efficacy outcomes
1. A vNRS pain score <3 at T-60.
2. A vNRS pain score reduction of at least 2 points out of
10 at T-60.
3. Pain scores at study time-points (T-30, T-60, T-90, T-120,
T-ME and T-XR).
4. ED length of stay, rescue analgesic in the 60 min following administration of study medication.
5. Time to effective analgesia, defined as the first vNRS
pain score <3 post-intervention.
6. Children’s self-reported pain intensity on the VAS and
the FPS-R at all study time-points.
Secondary safety outcomes
1. Any serious adverse events during the study period, including apnoea, cardiac arrest or death.
2. A Ramsay Sedation Score between 1 to 3.
3. Each specific adverse event type (eg, nausea, dizziness,
itchiness) during the study period.
4. Missed fractures or dislocations.
Secondary preference outcomes
1. Parent/caregiver’s reasons for choosing the opioid or
the non-opioid trial.
2. Self-reported parent/caregiver and child’s satisfaction
with pain relief and acceptability of study medications,
using a previously employed 5-point Likert scale.47
3. Physicians’ in-ED preference of analgesics for the patient.
4. Parent/caregiver’s comfort treating their child at
home, as measured by a scale created by the study
team.5
Sample size
The sample size for the three-armed opioid trial is 105
patients per arm, for a total of 315. The sample size for
the two-armed non-opioid trial is 85 patients per arm,
for a total of 170. Thus, the total for the No OUCH
Study would be 485. To account for missing data for the
primary outcome due to early withdrawal, the study will
over-recruit by approximately 10%, for a target recruitment of approximately 540 patients. This sample size was
determined based on a two-sided level of 0.05, a power
of 0.95, a minimally clinically important difference of 1.5
on the vNRS, an estimate of the SD of the difference of
2.748 and a Bonferroni correction to adjust for the three
6

treatment comparisons. Based on previously conducted
survey work,49 an imbalance in recruitment pace between
the opioid and non-opioid trials is expected. However,
both trials will continue to recruit until the sample size
is met for both. One trial will over-recruit to allow for
completion of the other, without compromising the key
preference-based study design. To ensure timely completion of the No OUCH Study, we will monitor the recruitment rates and potentially update the randomisation
strategy if there is an extreme over-recruitment for one
of the trials.
Statistical methods
All analyses will adhere to the principle of intention-
to-
treat. There will be three treatment comparisons:
(1) ibuprofen versus ibuprofen plus acetaminophen,
(2) ibuprofen versus ibuprofen plus hydromorphone,
(3) ibuprofen plus acetaminophen versus ibuprofen
plus hydromorphone. Due to homogeneity in the trial
endpoints for the two complementary trials, we will
consider a joint analysis across both the endpoints if the
two patient populations are sufficiently similar. This will
be determined using the following specified decision
rules.
For each treatment comparison, the primary analysis
will compare the mean vNRS reduction for pain scores
at T-60. This comparison will be facilitated using a linear
mixed model with the T-0 measure on the vNRS for pain
as a covariate and a site-specific effect. We will consider
whether the two trials can be analysed together used
nested linear mixed models with and without a trial by
treatment interaction term. If this interaction term is not
significant then a single treatment effect will be estimated
for each comparison. A two-sided level of 0.05 will be used
to declare significance. A Bonferroni-Holm correction
will be used to adjust for the three treatment comparisons.
The proportion of children with a self-reported vNRS of
less than 3 at 60 min, the proportion who require a rescue
analgesic by 60 min and the proportion who experienced
adverse events related to study drug administration will
be analysed using a Mantel-Haenszel χ2 test, stratified by
site. All other outcomes will be summarised using appropriate descriptive statistics.
There will be no interim analyses of the efficacy
endpoints, as it is very difficult to change practice based
on the results from small samples, regardless of the p
value. The Data Safety Monitoring Board (DSMB) will be
provided with a masked comparison between treatment
groups with respect to the safety endpoints at the intervals
of their choosing. The decision to stop the trial for safety
reasons will be left to the discretion of the DSMB (see
online supplementary appendix 3 for DSMB Charter).
Interim analyses will also monitor the relative recruitment rate of the two trials. If insufficient participants
are enrolled on either of the No OUCH trials, appropriate action will be taken to ensure sufficient power to
conclude following the completion of the trials. Further
Ali S, et al. BMJ Open 2020;10:e035177. doi:10.1136/bmjopen-2019-035177
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point reflects the peak plasma concentration and clinical
action of both oral hydromorphone and ibuprofen.28 43–45
The Principal Safety Endpoint will be the proportion of
children with adverse events related to study drug administration. Medication safety profiles influence parent/
caregiver and patient’s willingness to adhere to medication regimens.46 It has also been previously established
that more safety data is urgently needed to inform clinical decision-making when using the study medications of
interest.30
The Secondary Outcomes will include efficacy, safety
and preference endpoints:

Open access

Health economic methods
The trial will also examine the relative cost-effectiveness
of each of the medication options. The economic evaluation will take a healthcare perspective for the reference
case, in line with Canadian Agency for Drugs and Technologies in Health guidance50 and in secondary analyses
will consider societal costs. Information will be collected
on interventions during ED visit, in hospital medication
costs and follow-up care from other health services, as
well as on costs incurred by families in interacting with
health services. Quality of life will be measured by asking
parents/caregivers to report their child’s quality of life
using a 10-point numeric scale. The health economic
analysis will estimate the expected cost per incremental
change in quality of life and will use non-parametric bootstrapping methods to calculate uncertainty to assist in
decision-making about the value of providing different
treatment strategies.
Patient and public involvement
The team’s patient engagement partner (SH) has
provided ongoing input on the study protocol and data
collection tools. The study team was also supported
by parent advisory groups at the ECHO (Evidence in
Child Health to Enhance Outcomes) Research Program
(Edmonton, Alberta) and TREKK (Translating Emergency Knowledge for Kids) (Winnipeg, Manitoba). Parent
advisors reviewed and provided feedback on the wording,
readability, sensitivity, flow and content of parent/caregiver surveys. Following recruitment completion, parent
advisors will be engaged in focus groups to discuss study
results and dissemination plans in the context of family-
centred care.
Data management
Data management services will be provided by the WCHRI
data coordinating centre. Study data will be entered
and managed using REDCap (Research Electronic Data
Capture) tools hosted and supported by WCHRI.51
WCHRI’s REDCap installation is a validated electronic,
web-based data capture system housed in a secure data
centre at the University of Alberta.
Data will be entered directly into the study database or,
in case of technical failure, it may be collected on paper
and then digitally recorded in REDCap. Selected data
elements will be validated electronically on an ongoing
basis throughout the study and any discrepancies will be
assigned to members of the study team for resolution.
REDCap includes internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete or inaccurate (see online supplementary
appendix 4 for data management plan).
Only limited identifiable data will be stored in REDCap
(eg, email address) for the purposes of completing
follow-up surveys. Study participants’ contact information
Ali S, et al. BMJ Open 2020;10:e035177. doi:10.1136/bmjopen-2019-035177

will be stored securely at each clinical site for internal use
during the study. Paper records (eg, signed consent and
assent forms) will be stored in a secure locked cabinet at
each site, with limited access by the research team only.
At the end of the study, all records will continue to be
kept in a secure location for as long a period as dictated
by the reviewing REB, institutional policies or sponsor
requirements.
Monitoring
Monitoring for quality and regulatory compliance will be
performed by the University of Alberta’s Quality Management in Clinical Research (QMCR) office. QMCR is an
independent unit housed within the university’s central
length review of all
administration that provides arms-
University of Alberta sponsored trials, at least three times
per year. Details of clinical site monitoring will be documented in a Clinical Monitoring Plan.
Safety oversight will be under the direction of a DSMB
which will function independently of the investigators.
This committee will be chaired by Dr Garth Meckler
and is composed of five individuals with expertise in
trial methodology, epidemiology, biostatistics and paediatric emergency medicine. The DSMB will meet at least
semi-annually to assess safety and efficacy data and will
operate under the rules of an approved charter/terms of
reference.

Ethics and dissemination
Based on previously conducted research with oral
opioids,16 20 30 nausea, mild dizziness and drowsiness are
expected to be possible non-serious adverse events in this
study. There is a small potential risk of respiratory depression following the administration of any opioid, although
the risk is notably greater with repeat dosing and intravenous administration. This risk will be minimised by
using only a single oral dose and vigilantly monitoring
the participant’s vital signs and level of sedation during
the study period, which extends for 1 hour past the peak
action point of the drugs.
This study will be federally monitored by Health
Canada, and approval has been granted for the conduct
of this study (HC6-24-
c220455). The Research Ethics
Board at the University of Alberta has further approved
this study (Pro00073476). The five other participating
centres acquired ethics approval from their local REBs
prior to commencing recruitment. Any protocol amendments will be submitted for Health Canada review and
REB approvals prior to implementation and will be added
as an amendment to the C
 linicalTrials.gov registration.
Institutional approvals from each participating paediatric
ED will be obtained prior to beginning recruitment.
Public opinion regarding opioids is notably negative at
this time, thus there is a hesitancy to accept opioids, even
when they are felt to be clinically indicated. As such, it is
expected that some parents/caregivers will be hesitant to
accept opioids.52–54 However, the study will leverage this
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information is available in the Statistical Analysis Plan,
which will be published separately.
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